Skip to Main Content

Paper Details

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Cancer Immunol Immunother
82
2018
Author NameAffiliation
Bernd HeinrichCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Chi MaCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Qiong FuCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Milan SandhuCenter for Cancer Research, National Cancer Institute, National Institutes of Health
David AgdashianCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Qianfei ZhangCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Firouzeh KorangyCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Tim F GretenCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Tim F GretenNational Cancer Institute, Center for Cancer Research
  • 1 - 9

Datasets

Release 1.2